PFIZER INC: $661M Department of Health and Human Services Contract Vehicle
Summary
Pfizer Inc ($PFE) received a $661M contract from the CDC for the Vaccines for Children program, representing ~1.1% of its annual revenue. This award reinforces Pfizer's position in the pediatric vaccine market and provides a stable, government-backed revenue stream. While not transformative, it is a meaningful addition to Pfizer's top line.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Pfizer secured a $661M CDC contract for pediatric vaccines, representing ~1.1% of annual revenue.
- 2.The contract provides stable government-funded revenue for Pfizer's vaccine segment.
- 3.No direct legislative connection, but broader healthcare bills support preventive care funding.
Market Implications
For Pfizer ($PFE), this contract adds predictable top-line growth and reinforces its vaccine franchise. The stock may see modest positive sentiment, but the impact is limited given the contract's size. Supply chain partners like Catalent ($CTLT) and Thermo Fisher ($TMO) could see minor benefits from increased production needs. Overall, this is a routine but positive development for Pfizer's healthcare segment.
Full Analysis
The Department of Health and Human Services, through the Centers for Disease Control and Prevention, awarded Pfizer Inc a $661M indefinite delivery/indefinite quantity contract for the Vaccines for Children program. This program provides vaccines to children who might not otherwise be vaccinated due to financial barriers. Pfizer is a leading vaccine manufacturer with products like Prevnar 13 and Prevnar 20, making it a natural recipient for such contracts.
Pfizer's FY2025 revenue was $59.6B, so this contract accounts for about 1.1% of annual revenue. While not a game-changer, it adds predictable government-funded revenue to Pfizer's vaccine segment, which has seen volatility post-COVID. The contract runs from April 2026 to March 2027, providing near-term visibility.
No specific legislation directly authorizes this contract; it falls under existing CDC programs. However, related healthcare bills (HR10086, HR10087, HR10100) indicate ongoing congressional focus on preventive care and disease management, which supports sustained funding for vaccination programs.
Supply chain beneficiaries include vaccine component suppliers and logistics providers. Key subcontractors may include companies like Catalent ($CTLT) for manufacturing support and Thermo Fisher Scientific ($TMO) for cold chain logistics. These companies could see incremental demand from Pfizer's increased vaccine production.
Historically, large vaccine contracts from the CDC provide stable revenue for pharmaceutical companies. Pfizer's previous involvement in the Vaccines for Children program has contributed to consistent segment performance. This award reinforces that trend and supports Pfizer's long-term growth in vaccines.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Direct contract award for vaccine supply under the Vaccines for Children program
Who must act
Centers for Disease Control and Prevention (CDC) awards $661M to Pfizer Inc
What happens
$661M added to Pfizer's revenue over the contract period (April 2026 - March 2027), representing approximately 1.1% of FY2025 revenue of $59.6B
Stock impact
Strengthens Pfizer's vaccine segment, which is a core business line. The contract provides predictable government-funded revenue, supporting stable cash flows. Pfizer's vaccine portfolio includes Prevnar and other pediatric vaccines, aligning with this award.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
HELP Copays Act
Wildlife Health Coordination and Zoonotic Disease Prevention Act of 2026
A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
A bill to provide for digital communication of prescribing information for drugs (including biological products), and for other purposes.
A bill to require regulatory review of pharmaceutical products from Chinese entities, and for other purposes.
Expedited Access to Biosimilars Act
TREAT PTSD VA Act
A bill to require continued participation by the United States in the World Health Organization, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Contract Details
Recipient
PFIZER INC
Award Amount
$661,393,280
Awarding Agency
Department of Health and Human Services
Sub-Agency
Centers for Disease Control and Prevention
Contract Type
INDEFINITE DELIVERY / INDEFINITE QUANTITY
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →